A deescalation strategy involving switching from ticagrelor to clopidogrel in patients with acute myocardial infarction (AMI) ...

An updated guideline has been published by the AHA, ACC, and other organizations regarding the management of acute coronary syndrome.

For patients with ACS undergoing DES implantation, de-escalating DAPT to P2Y12 inhibitor monotherapy is associated with lower bleeding risk.

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

AstraZeneca’s chief exec Pascal Soriot says Brilinta is on track to break through ... The patients being studied were taking low-dose aspirin but still at high risk of an atherothrombotic ...

Scientists studying how cancers spread have found that aspirin may help prevent metastases, or secondary tumors, by boosting the body’s immune response. In their mouse study, aspirin helped ...

The filing was based on results from the phase 3 THALES trial, which showed aspirin plus Brilinta 90 mg used twice daily for 30 days resulted in a statistically significant and clinically ...

Share on Pinterest Research in mice shows how aspirin may boost the immune response against cancer, keeping secondary tumors at bay. Image credit: AsiaVision/Getty Images. Around half of all ...

Perhaps prasugrel or ticagrelor may have a major role in patients with so-called clopidogrel resistance. One issue that still remains is the (un)certainty of defining the latter phenomenon. The ...

particularly with ticagrelor, is often appropriate, reserving longer-duration DAPT for those with highest ischaemic risk but where bleeding risk is not high. A body of trial evidence now supports this ...